PREDICTIVE TECHNOLOGY GROUP APPOINTS DR. MICHAEL DEY TO BOARD OF DIRECTORS

CEO of Predictive Therapeutics and Former Wyeth Women’s Health Executive Joins Predictive Technology Group Board of Directors

Salt Lake City, UT — January 2, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED), announces the appointment of Michael Dey, Ph.D. to the Board of Directors of Predictive Technology Group, Inc.  Dr. Dey will assist in corporate governance and guide the development and commercialization of technology and products in all PRED subsidiaries.

In addition to serving as a PRED Board Member, Dr. Dey will continue as Chief Executive Officer of Predicitive Therapeutics, Inc., a wholly owned subsidiary of PRED.  Before joining PRED, Dr. Dey had executive positions at Wyeth, later acquired by Pfizer, where he was both the President and the President of Scientific Affairs division for Wyeth’s Women’s Health Care business.  As President of Wyeth’s Women’s Health Care business for seven years, Dr. Dey managed its global resources of more than $3 billion annually.

“We are very pleased to have Mike join PRED’s Board of Directors,” said Bradley Robinson, CEO of PRED. “Mike’s breadth of knowledge and experience in life sciences will greatly assist in advancing science and technology and bringing related diagnostics and therapeutics to the clinic to improve the care and outcomes of patients.”

Before his leadership role in women’s health care, Dr. Dey served as Vice President, General Manager of ESI Pharma, Inc. In 1995, with Wyeth’s acquisition of American Cyanamid and Lederle Standard Products, Dr. Dey became President of ESI Lederle, Inc.  As President of ESI Lederle, Dr. Dey’s responsibilities included directing one of the largest generic companies in the U.S. with more than $500 million in sales, approximately 150 people in R&D and 100 people in marketing and sales. ESI Lederle sold both oral and injectable products that included Tubex®, the prefilled syringe delivery system.

Dr. Dey received an undergraduate degree in Biology/Chemistry in 1973, a Master’s Degree in 1980 in Pharmacology and Toxicology and a Ph.D. in 1984 in Pharmacology and Toxicology.

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the treatment of endometriosis. Dr. Dey’s appointment will assist PRED to reach these commercial milestones effectively.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Predictive Technology Group, Inc. (PRED) Announces Issuance of U.S. Patent for Method of Treating Endometriosis

Issuance Strengthens Commercialization Strategy of Company’s Gene-Based Endometriosis Diagnostics and Therapeutics

Salt Lake City, UT – December 28, 2017- Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announced today the issuance of U.S. patent 9,840,738 directed to treating patients genetically predisposed to endometriosis.

Endometriosis, a common gynecologic disorder estimated to affect 1 in 10 women in their reproductive years – equates to approximately 176 million women in the world.  U.S. patent 9,840,738, builds on the coverage provided by previously issued US patent 8,932,993

“This technology brings a significant opportunity for PRED and to the healthcare market, assisting women and their physicians in designing a course of care that places women on the most appropriate therapy at the earliest possible stage of disease progression,” said Bradley Robinson, President and Chief Executive Officer of PRED. “The rights to this technology are seen as a synergistic companion to the therapeutic products PRED intends to bring to market.”

Bradley Robinson described the claims of U.S. patent 9,840,738 as covering any treatment of endometriosis in women, whether symptomatic or not, having any one (or more) of approximately 1,400 endometriosis-associated genetic markers.

About Predictive Technology Group, Inc. 

Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding Company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com. 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

 

 

PREDICTIVE TECHNOLOGY GROUP APPOINTS JOHN E. SORRENTINO TO CHAIR PREDICTIVE THERAPEUTICS’ SCIENTIFIC ADVISORY BOARD

PREDICTIVE TECHNOLOGY GROUP APPOINTS JOHN E. SORRENTINO TO CHAIR PREDICTIVE THERAPEUTICS’ SCIENTIFIC ADVISORY BOARD

Salt Lake City, UT — December 26, 2017 — Predictive Technology Group, Inc. (OTC PINK: PRED) announces that John E. Sorrentino, will chair the Predictive Therapeutics’ Scientific Advisory Board. Predictive Therapeutics, a wholly owned subsidiary of Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine. Sorrentino is Vice President and Chief Operating Officer of Vaccine Research and Development at Pfizer and brings his vast experience in R&D and clinical laboratory management to the Predictive Therapeutics’ Advisory team.

Sorrentino has over 35 years of senior management experience in the life sciences. Focused on improving public health, he has held leadership roles in private, and public companies, as well as government and non-profit institutions. Prior to joining Wyeth, later acquired by Pfizer, 14 years ago, Sorrentino held executive positions in several organizations that provided neonatal screening and related clinical services.  Sorrentino’s expertise has had him appear before state legislators, the US Congress and professional societies on a variety of healthcare and policy issues.

“We are very pleased to have John head up our Scientific Advisory Board,” said Dr. Mike Dey, CEO of Predictive Therapeutics and former Wyeth colleague. “John’s experience in clinical testing and women’s health will be an invaluable addition to our current team of experts and our mission to effectively treat endometriosis.”

“I am excited to chair the Predictive Therapeutics’ Scientific Advisory Board,” said John Sorrentino. “The work they are doing in genetic testing has potential to ultimately assist mothers and their children in knowing if they need therapeutic treatment and could improve health outcomes.”

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Northstar Electronics, Inc. (NEIK) Progress Update on Deal With Major Aerospace Manufacturer

Vancouver, British Columbia-October 25, 2017 – Northstar Electronics, Inc. (OTCQB:NEIK) previously stated that its subsidiary, Northstar Sealand Enterprises Ltd. (NSEL), is working to acquire the worldwide rights to a “Turbo-Prop” single engine industrial airplane from a world leader in the aerospace industry.  The timeline for the final agreement with the subsidiary company that owns the rights to the airplane has been extended. The main reason is that there is a strong possibility that the parent company will use our transaction as an “Offset,” which means that much of our acquisition costs included the Intellectual Property (IP), prototype, tooling, etc. would be covered (when international companies win large multi-billion contracts from the Canadian government, the companies have obligations to put considerable work into local companies.)

As mentioned before, the primary applications for the airplane are in “Agriculture and Rapid Response Forest Fire Fighting” where the needs for both types of airplanes are high. NSEL is continuing its assessment of the “Cloud Seeding” market. So far, the results look positive. Management believes the new design features of the NSEL airplane will quickly lead to it being a leader in its class.

Once the airplane “Rights Acquisition Agreement” is signed, NSEL intends to aggressively roll out its plans to initiate the actions leading to manufacturing the airplane and marketing it worldwide. The Company`s basic marketing strategy is to first focus on markets in which the former version of the plane was a big success, with many of those customers expressing considerable interest in the new, innovated version.  NSEL plans to then expand outwards to other markets, domestic and foreign, where there are also strong needs for the performance capabilities of this new design.

NSEL’s estimates for annual revenues in the fifth year of operations are of the order of $30M, with good profit margins.

On another note, Northstar is pleased to report that a former senior executive at the world’s largest defense and aerospace company has become an advisor to the Company. He has a stellar background and brings extensive international experience to the Company.

Dr. Wilson Russell, CEO of Northstar Electronics, comments, “Although the timeline to an agreement has been extended, the potential resulting benefits are highly significant to Northstar. It also means that we would likely have the support of the parent company for up to five years going forward. ”

Currently, Northstar wishes to raise funds. The instrument is comprised of a common share plus a warrant. Northstar is looking for investors who would like to be part of what we believe is an attractive opportunity in the growing Aerospace industry. Interested parties can contact Wilson Russell, CEO, at wrussell@northstarelectronics.com.

For further information about this news release contact, Rich Kaiser, Investor Relations, Yes International, 757-306-6090, yes@yesinternational.com.

About Northstar Electronics, Inc.

Northstar Electronics, Inc. (OTCQB:NEIK) established in the late 1990’s carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. Since termination of the above contracts, Northstar has moved towards making and selling its own independent systems, www.northstarelectronics.com.

Safe Harbor Statement:
This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.

DOYEN ELEMENTS INC.’S Stock Subscription Offering Now OPEN

September 12, 2017

Dear Investors,

DOYEN ELEMENT, INC. can now sell to both accredited and non-accredited investors shares of its stock, offering Seven Million (7M) shares at Seven US Dollars ($7.00) per share under the effective registration.

Please use promo code YES INTL in the section of the offering agreement upon submitting your subscription agreement; http://www.doyenelements.com/invest/ provides the necessary information to proceed forward with the stock subscription offering in becoming a shareholder in DOYEN.

DOYEN’s unique and novel business model provides ALL services as they pertain to the medical cannabis industry everything from building space to distribution. The Company is NOT directly involved in the actual growing of cannabis but provides a turn-key solution to producers. These solutions enable the Company to generate revenues and to grow its footprint in the medical cannabis space in Colorado, USA.

If you have any questions on the sale of shares registered under the Regulation A, Tier II offering, please contact us with any and all questions, regarding this 7M at $7.00 per share offering, rich@yesinternational.com, 757-306-6090.

With Warmest Regards,

/s/

Rich Kaiser
Investor Relations- DOYEN ELEMENTS, INC.
www.doyenelements.com
rich@yesinternational.com
757-306-6090

Disclaimer: An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that Doyen Elements, Inc. may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement here. You should read the offering circular before making any investment.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) EVALUATES UP-LISTING TRADING STATUS TO OTCQB

Salt Lake City, UT- September 11, 2017- Predictive Technology Group, Inc. (OTCPINK: PRED) proceeds with the evaluation of moving the Company’s trading status to OTCQB on OTC MARKETS.

Management determined the “NEW” Alternative Listing Standards which became available to issuers could be prudent, saving time and cost effective objective to uplift PRED’s tradable shares.

Effective May 18, 2017, the OTC Markets amended its rules for the OTCQB qualification which allows the issuers that follow “Alternative Reporting Standard.”  The new standard for OTCQB for alternative reporters now allows a company to file 1-year audited financial reports.  These reports are to US GAAP standards through a PCAOB qualified auditor.   A company must still maintain a bid price of $0.01 per shares, needs a board of directors with at least two independent directors, and an audit committee comprised of a majority of independent directors.

OTC MARKETS believes these updated rules for OTCQB provides non-SEC Reporting companies with the benefits of public trading while lowering the cost and complexity of being public. The new market standards give “Alternative Reporting” companies an efficient way to raise their profile among the investor and broker dealer communities, access greater liquidity, and trade on a SEC-recognized market. Thus, removing the trading restrictions placed on “Pink” market securities.

Based on these news standards, PRED’s management remains confident that uplifting to the OTCQB can be done timely. Once management and the board at PRED finish their due diligence on OTC MARKETS’ “ALTERNATIVE REPORTING STANDARDS,” expect more news to follow.

Management continues on its fiduciary path with a primary objective of creating shareholder value.

About Predictive Technology Group, Inc.:

Predictive Technology Group, Inc. (OTCPINK:PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products effectively designed to prevent and treat diseases.

For further information about PRED and this release contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com, www.predictivetechnologygroup.com.

 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

 

Contact

Rich Kaiser

YES INTERNATIONAL

757-306-6090

yes@yesinternational.com

www.predictivetechnologygroup.com

www.predbiotech.com

www.predrx.com

 

DOYEN ELEMENTS INC.’S USSEC REGISTRATION EFFECTIVE, PROCEEDING WITH SALE OF 7 MILLION SHARES

September 2, 2017

Dear Investors,

The United States Securities and Exchange Commission (USSEC) as of yesterday, Friday, September 1, 2017, informed DOYEN ELEMENTS, INC.’s (DOYEN) management that its Regulation A, Tier II, Registration Statement became effective.

The effectiveness now allows DOYEN to sell to both accredited and non-accredited investors shares of its stock, offering Seven Million (7M) shares at Seven US Dollars ($7.00) per share under the effective registration.

DOYEN’s unique and novel business model provides ALL services as they pertain to the medical cannabis industry, everything from building space to distribution. The Company is NOT directly involved in the actual growing of cannabis but provides a turn-key solution to producers. These solutions enable the Company to generate revenues and to grow its foot print in the medical cannabis space, not only in Colorado but soon in other states permitting medical marijuana.

NOW with the USSEC approval, the Company can attract investors into this novel idea of providing ‘A-Z’ services in the medical cannabis industry space.

DOYN received numerous news reports regarding its business fundamentals in the cannabis medical space in Colorado, USA. These reports, social media postings/interactions, and direct contacts created a “BUZZ” within the domestic and international investment communities who expressed interest in becoming shareholders. Such a “BUZZ” can sometimes create enormous demand and interest in this type of share registration.

Management hired CROWDFUNDX who is leading the digital and paid marketing campaign to drive investor awareness for the offering. Management’s objective to fully sell-out the 7M share offering for an aggregate value of $49 Million US Dollars, and then proceed with this “crowd financed” IPO to hopefully list on a major stock exchange in the near future.

During the week of September 3, 2017, interested parties can expect the opening of the registered sales for those who might like to participate in the 7M share offer (second email to follow on “OPENING”).

This historical event for the operations at DOYEN ELEMENTS, INC. could be an enormous opportunity for ALL involved, if you have any questions on the sale of shares registered under the Regulation A, Tier II offering, please contact us with any and all questions regarding this 7M at $7.00 per share offering, YES INTERNATIONAL, 757-306-6090.

Contacts for DOYEN ELEMENTS, INC.:

Rich Kaiser
YES INTERNATIONAL
Investor Relations- DOYEN ELEMENTS, INC.
www.yesinternational.com
rich@yesinternational.com
757-306-6090

Darren Marble
CROWD FUND X
www.crowdfundx.io
darren@crowdfundx.io
310-710-9920

Olivia Mannix
CANNABRAND
Media Relations-DOYEN ELEMENTS, INC.
www.cannabrand.uc
olivia@cannabrand.us
303-223-7411

DOYEN ELEMENTS, INC.
Info@doyenelements.com
www.doyenelements.com
800-511-5925

Disclaimer: An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that Doyen Elements, Inc. may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement here. You should read the offering circular before making any investment.

Bravo Multinational Incorporated (BRVO) Reports On Project Reviews Including Move Into MJ Sector

Toronto, Canada- August 29, 2017- Bravo Multinational Incorporated (BRVO:OTCQB) announces its current review of a potential new “Casino Gaming” operation venture and review of diversified business opportunities in the legalized marijuana (MJ) sector in Canada.

BRVO began an extensive review of a large pending commercial “Marijuana Grow“ operation with related real estate holdings for a possible joint-venture investment, located in Central Ontario, Canada. The licensing process for this venture is currently pending Health Canada’s government approvals. Upon approval, the business intends to operate both indoor hydroponic, and outdoor natural grow operations.

The Company has entered discussions for a potential partnership opportunity into a new “Medical Marijuana Assessment” business with an existing medical marijuana (MMJ) sector assessment program professional.  The business intent would be the opening of 4-6 medical marijuana assessment clinics in the greater Metro Toronto area for “fee for service” cliental. Upon government approval, the intended future addition of “Dispensary License” permits may be applied to each clinic providing on location direct MMJ sales.

In the gaming sector, the Company is reviewing potential new “Casino Gaming” locations in an affluent community in a Pacific Coast City of Nicaragua. Bravo intends on opening a large stand alone “Casino Slot Palace.“ Through Bravo’s existing “Casino and Gaming License” connections and equipment inventory, the Company anticipates a smooth approval and set-up process. Research indicates that there is only one gaming operation currently set-up in this large community, servicing both the tourist and local markets.

A recent press release announced an “Asset Purchase Closing,” completed on August 16, 2017. The  Company reports the completion of the “placement” all 300 gaming machines, now resulting in immediate revenue generation for the Company.

In addition to the herein mentioned “Under Review” potential projects, the Company’s management continues to explore and assess several other future business opportunities that would be beneficial to both BRVO’s asset valuations and revenue generation.

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTCQB:BRVO) is a diversified company with the main focus being on the growth of our casino gaming equipment holdings. Currently, Bravo’s gaming equipment assets located in Central and South America. Bravo also holds patented mining claims in the gold and silver district on War Eagle Mountain, USA. Bravo’s current and future growth strategy, driven by partnerships, new acquisitions, and ventures should result in financially viable and profitable long- term operations throughout the Americas.

For further information contact Bravo Multinational Incorporated, www.bravomultinational.com, info@bravomultinational.com and (716) 803-0621

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by other factors. Such factors, including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

Bravo Multinational Incorporated (BRVO) Closes Transaction on 300 Casino Gaming Machines and Uplists Trading onto OTCQB

Toronto, Canada- August 21, 2017- Bravo Multinational Incorporated (OTCQB:BRVO) completed an asset purchase on August 16, 2017, for 300 slot and video poker machines, providing an immediate new revenue stream for Bravo. The contract valued at $3,618,000, with the Company anticipating an approximate 30% annual return on these assets in Latin America based on historical income data in similar locations.

Effective August 18, 2017, the Company upgraded its shares to the QB trading platform on OTCMARKETS.COM (OTCQB.BRVO). The OTCQB trading platform allows the Company to obtain greater market exposure as it initiates its next steps and advances the growth of the business.

Diligently, BRVO works on additional advancements of new business ventures to enhance the Company’s asset portfolio with potential projects in both North America and Central America. Stay tuned for the next report(s).

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTCQB:BRVO), a diversified Company, with its main focus being on the growth of its casino gaming equipment holdings currently has gaming equipment assets located in Central and South America. Bravo also holds patented mining claims in the gold and silver district on War Eagle Mountain, USA.  Bravo’s current and future growth strategy, driven by partnerships, new acquisitions, and ventures should result in financially viable and profitable long-term operations throughout the Americas.

For further information contact Bravo Multinational Incorporated, www.bravomultinational.com, info@bravomultinational.com and (716) 803-0621

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward-looking statements on behalf of the Company may be affected by other factors. Such factors, including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

HELLENIC COIN (LIVECOIN:HNC) ANNOUNCES SPONSORSHIP ON CRYPTOCURRENCY TRADE PLATFORM LIVECOIN.NET

New York City-   August 10, 2017- HELLENIC COIN (LIVECOIN:HNC) announces the full-month of August 2017 sponsorship on LIVECOIN.NET, the coin’s primary exchange trading platform. The sponsorship gives $HNC a premier visibility on the exchange to all the active traders in cryptocurrencies.

LIVECOIN.NET is a modern service for accessing cryptocurrency exchange markets, providing a comfortable, practical and profitable platform with which to work with cryptocurrencies – suitable for both beginners and experienced traders.  Opening an account is straightforward.

HELLENIC COIN’s main objective is to bring more knowledge, information, and trading fundamentals about this growing cybercurrency, as it becomes more widely accepted in all forms of commerce.

Pending announcements regarding increases in HNC’s worldwide acceptances in a vast and variety of industries, coupled with new partnerships, HNC’s management expect continued growth.  As such, HNC’s value and its coin volume transactions are increasing, accordingly.

$HNC is limited by a 100 million currency unit cap, with only 61,700,000 million currently mined coins.  HNC positioned its self as an alternative currency, whereas the world’s FIAT currencies appear to be under devaluation pressures.

Currently, HELLENIC COIN launched a massive marketing program which includes news sourcing, social media interactions, print and digital articles, direct and online contacts, and exchange sponsorships.

For more information about Hellenic Coins, its trading platform on Livecoin.net, and merchant acceptances, contact, Rich Kaiser, YES INTERNATIONAL, www.yesinternational.com, 757-306-6090, and yes@yesinternational.com.

ABOUT HELLENIC COIN

HELLENIC COIN ($HNC) established in 2015 uses the technology of “LiteCoin” coin, similar to “BitCoin,” with different algorithms and blockchain. With the world economies in flux and uncertainty, HNC provides the world with an alternative currency the people can believe in, backed by precious metals, carbon credits, and leading cryptocurrencies.  HNC positioned itself to be an aggressive coin in the cryptocurrency sector which has an ever increasing stored value and wider acceptability in monetary transactions, www.helleniccoin.com.